Why the "Wtf"? This is just a typical OBMP day...
A lot of it is still discussed on the Stock Market thread.AgShaun00 said:
this thread got quiet.
AVEO has a pretty good entry right now at $2tamc1956ag said:
Okay, I'm a novice investor, which bio stock do you recommend? I have a fairly long timeline..2-5 yrs
This one has been sucking ass for a couple months and putting a nice drag on my bios....along with all the other ones.09Ag said:
AIMT up 16% today with a quarter full of catalysts on the way!
tamc1956ag said:
sounds like AVEO is running out of money..
Gabster43213 said:
1956Ag,
I am thinking about buying another 35,000 shares of OBMP for about $500. Final site visit for their Phase 2 trial was held last week at Harvard. Trial will begin in January. Some who have followed the company and their cancer drug Proscavax for the past several years believe the company could be bought beginning mid-late summer for $1.50 - $2.00 a share.
What it means, I have no idea... This thing is under a penny and has been for awhile. Still just a lottery ticket.Chief 12 said:
Any news on OBMP, Gabster?
I see that OBMP was over $50/share when it opened in 2010 then dropped down to ~ $5 in 2012-2013 before popping back up in 3Q2013 to over $80, hovering around $40 for six months or so and then tailing off to the now less than a penny.IrishTxAggie said:What it means, I have no idea... This thing is under a penny and has been for awhile. Still just a lottery ticket.Chief 12 said:
Any news on OBMP, Gabster?
https://markets.businessinsider.com/news/stocks/oncbiomune-announces-agreement-with-cato-bioventures-as-a-strategic-investor-in-support-of-cd71-targeted-therapy-for-refractory-cancers-1028158233
Quote:
Overview
We are a biotechnology company specializing in innovative cancer treatment therapies. We have proprietary rights to an immunotherapy platform with an initial concentration on prostate and breast cancers that can also be used to fight any solid tumor. Additionally, we have targeted therapies. Our mission is to improve the overall patient condition through innovative bio-immunotherapy with proven treatment protocols, to lower deaths associated with cancer and to reduce the cost of cancer treatment. Our technology is safe, and utilizes clinically proven research methods of treatment to provide optimal success of patient recovery.
Financial Highlights
For the three months ended March 31, 2019, we utilized $286,329 to fund our operations, compared to $433,878 for the three months ended March 31, 2018. For the three months ended March 31, 2019, we received net cash of $286,628 from financing activities. As a result, our net cash position decreased by $201 during the three months ended March 31, 2019.
...
We expect our research and development expenses will continue to increase as our ProscaVax clinical trials continue to progress.
09Ag said:
Bio has been hot lately. Anyone else profit from that 100% gain from positive AUPH data? My main stock AIMT finally recovered from the downtrend and should be getting FDA approval any day now. Looks like OBMP is officially dead.
Depends on how bad it gets (or how much fear is ginned up), but some to look at:akaggie05 said:
Bump for any Coronavirus plays... who's got em?
Aggierific said:
Great idea. I'll just take all my profits from the great obmp play and dump then into Corona stocks.